Philanthropic support Non-confidential Let's talk ↗
Support scientific value creation. Philanthropic funding can accelerate defined preclinical research and help GenLumina unlock additional public, strategic and private capital. Donations are separate from investment and do not provide equity or commercial rights.
Support precision oncology

Help move a new cancer technology closer to patients.

GenLumina is developing a spatially activatable intracellular payload platform for targeted oncology. Philanthropic support can fund the evidence needed to advance the technology through its next preclinical milestones. Every delay in this development has a human cost.

Discuss philanthropic support ↗
Research first.
Leverage next.

Well-directed philanthropic capital can finance scientific milestones that strengthen the case for grants, strategic collaborations and subsequent private investment.

02 — WHO CAN SUPPORT

Different forms of giving. One development pathway.

The support route can be matched to the donor's mandate, desired level of involvement and the scientific milestone to be funded.

Foundations

Fund defined research

Support a clearly scoped preclinical programme or milestone aligned with a foundation's oncology, innovation or patient-impact mission.

Discuss a programme →
Major donors

Accelerate a milestone

Direct substantial philanthropic support toward scientific evidence generation and the transition to the next development stage.

Talk to GenLumina →
Public support

Contribute directly

Individual contributions can support GenLumina's research mission and help build momentum around a new approach to precision oncology. Every contribution helps us move faster, and your support is deeply appreciated.

Donation route →
03 — WHY PHILANTHROPY

Use philanthropic capital where it can have catalytic effect.

GenLumina has already secured approximately €1 million for preclinical research together with LUMC and the Netherlands Cancer Institute. Additional support can help accelerate the next evidence-generating steps.

Scientific impact

Support preclinical validation, including evidence around efficacy, targeting, conjugation, activation and safety as programmes progress.

Funding leverage

Strong scientific evidence can improve GenLumina's ability to attract public co-funding, pharma collaboration and private capital for subsequent development.

04 — DEVELOPMENT LOGIC

From contribution to value-inflection point.

Rather than promising that a donation directly finances late-stage clinical activity, this page focuses support on the development stage GenLumina is actually advancing now.

01Philanthropic supportFunding directed to an agreed research objective.
02Preclinical evidenceGenerate data around the platform and targeted applications.
03De-risk & leverageUse stronger evidence to unlock additional financing and partnerships.
04Advance developmentMove the programme toward IND-enabling and future clinical development.
05 — CLEAR SEPARATION

Donate, invest or partner.

GenLumina maintains separate routes for philanthropic support, financial investment and pharmaceutical partnering. This allows each stakeholder to participate through the structure that fits its mandate.

Investment opportunities → Pharma partnering →
SUPPORT GENLUMINA

Help us move faster. Every delay has a human cost.

For foundations, major donors, philanthropic organisations and individual supporters, your help is much appreciated. We can discuss a defined research objective, or you can contribute directly to help accelerate the next preclinical milestones.

Donate now ↗ Discuss philanthropic support →